Iovance Biotherapeutics
IOVA
₹160.40
Share price
-3.11%
Change (1 day)
-77.25%
Change (1 year)
Categories
Iovance Biotherapeutics (IOVA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : ₹17.05 Billion
According to Iovance Biotherapeutics 's latest financial reports the company's total liabilities are ₹17.05 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Iovance Biotherapeutics - Total liabilities on balance sheet (from 2008 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | ₹17.15 B | 5.3% |
| 2023-12-31 | ₹16.29 B | 19.82% |
| 2022-12-31 | ₹13.59 B | 17.37% |
| 2021-12-31 | ₹11.58 B | 41.51% |
| 2020-12-31 | ₹8.18 B | 151.34% |
| 2019-12-31 | ₹3.25 B | 218.51% |
| 2018-12-31 | ₹1.02 B | 61.94% |
| 2017-12-31 | ₹0.63 B | 87.09% |
| 2016-12-31 | ₹0.33 B | 211.66% |
| 2015-12-31 | ₹0.10 B | 2.84% |
| 2014-12-31 | ₹0.10 B | -24.89% |
| 2013-12-31 | ₹0.14 B | -77.43% |
| 2012-12-31 | ₹0.62 B | -12.01% |
| 2011-12-31 | ₹0.70 B | 1815.19% |
| 2010-12-31 | ₹36.87 M | 3337.15% |
| 2009-12-31 | ₹1.07 M | 570.65% |
| 2008-12-31 | ₹0.15 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 NRC Health
NRC | ₹9.04 B | -46.95% | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | ₹0.27 B | -98.42% | Bahamas |